Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon to Develop microRNA-Detection Products for Luminex's xMAP Platform

NEW YORK (GenomeWeb News) – Luminex and Exiqon said today that they have signed an agreement to co-develop and commercialize microRNA products for Luminex’s xMAP platform.
 
Under the terms of the agreement, Exiqon will develop and manufacture microRNA detection chemistries on behalf of the Luminex Bioscience Group.
 
The final microRNA products will be based on Luminex's xMAP instruments and Exiqon's Locked Nucleic Acid probes, nucleotide analogs that bind to RNA and DNA targets.
 
“By including LNAs in detection probes, it is possible to design very specific high-affinity detection assays for small RNA targets like miRNAs, which otherwise would not be possible using standard DNA-based detection probes,” the companies said in a statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.